SOUTH SAN FRANCISCO, Calif., July 1, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the Cantor Fitzgerald Inaugural Healthcare Conference in New York, NY. Dr. Ian Friedland, Chief Medical Officer, is scheduled to present on Wednesday, July 8th at 11:45 a.m. Eastern Time, at the Le Parker Meridien Hotel, New York, NY.
A live webcast of the presentation can be accessed by visiting the investor relations section of the Achaogen website at http://investors.achaogen.com/. A replay of the webcast will be archived for at least 30 days following the presentation.
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen's lead product candidate, for the treatment of serious lung, bloodstream, and urinary tract infections due to Enterobacteriaceae, including, but not limited to, carbapenem-resistant Enterobacteriaceae (CRE). Achaogen's plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen's gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.